• Exosome research tools commercially available through global distribution partner
• Clinical-stage OC screening test and BC monitoring test
• Preclinical-stage next-gen exosome therapeutic in development for TNBC

INOVIQ is a leading exosome company with a proven technology platform and a portfolio of research tools, diagnostics and therapeutics. The company's key achievements in FY25 include expanding its exosome platform, partnering diagnostic programs, accelerating the development of exosome therapeutics, and growing revenues. INOVIQ's exosome research tools are commercially available through a global distribution partner, generating initial revenue with potential for future licensing income. The company also has a clinical-stage ovarian cancer (OC) screening test, EXO-OC, which has demonstrated high sensitivity and specificity in a retrospective case-control study. INOVIQ is planning further validation studies and a multi-stage commercialization strategy to rapidly make the EXO-OC test available to women worldwide. Additionally, INOVIQ has a preclinical-stage CAR-exosome therapeutic in development for triple-negative breast cancer (TNBC), which has shown promising in vitro results. The company is focused on partnering and strategic acquisitions to expedite commercialization and growth, with significant upside potential in its FY26 catalysts.

INOVIQ is positioned to become a leading exosome company with best-in-class diagnostics and therapeutics for cancer. Over the next 2 years, the company aims to: expand its EXO-NET customer base by over 200% and secure its first diagnostic partner; partner the EXO-OC test for LDT commercialization and progress IVD development; generate in vivo data for the CAR-EV TNBC program and commence IND-enabling studies; partner the NeuCA15-3 test; and deliver year-over-year growth across partner, product and revenue metrics.